Association between gut dysbiosis and chronic kidney disease: a narrative review of the literature

Zhe Feng¹, Ting Wang¹, Sheng Dong¹, Hongli Jiang², Jianzhong Zhang³, Hafiz Khuram Raza³ and Genping Lei¹,²

Abstract
Chronic kidney disease (CKD) is a serious non-communicable disease that poses a significant burden on healthcare and society. It is essential to devise new strategies to better treat patients with CKD. Research has illustrated that gut dysbiosis, describing an abnormal intestinal ecology, is closely associated with CKD. In this narrative review, we summarized the evidence of their mutual relationship and discussed the potential treatment options to correct gut dysbiosis in patients with CKD. Gut dysbiosis significantly increases the risk of CKD, especially in the older population. Gut dysbiosis also plays a role in CKD complications, such as hypertension, cardiovascular events, and cognitive dysfunction. The relationship between gut dysbiosis and CKD is bidirectional, and CKD itself can lead to changes in gut microecology. The usual therapies for CKD can also increase the incidence of gut dysbiosis. Meanwhile, probiotics and antibiotics are generally used to correct gut dysbiosis. Further studies are required to elaborate the association between gut dysbiosis and CKD, and more treatment options should be explored to prevent CKD in patients with gut dysbiosis.

Keywords
Chronic kidney disease, gut dysbiosis, probiotics, antibiotics, hypertension, gut microecology, prebiotics

Date received: 25 May 2021; accepted: 22 September 2021

¹Department of Nephrology, Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi, China
²Dialysis Department of Nephrology Hospital, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
³Unimed Scientific Inc., Wuxi, China

Corresponding author:
Genping Lei, Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, No. 2, Weiyang West Road, Qindu District, Xianyang, Shaanxi 712000, P. R. China.
Email: leigenping2006@163.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Chronic kidney disease (CKD) exerts a significant burden on the healthcare system, society, and the economy. Epidemiological studies revealed that the prevalence of CKD is 10.8% in China\(^1\) and 13% in the US\(^2\), whereas the global prevalence ranges 8% to 16\(^3\). The financial impact of CKD is approximately $48 billion per year in the US\(^4\). Therefore, it is essential to explore its pathogenesis and devise new treatment strategies. An abnormal gut environment has been revealed to be closely associated with CKD. A global study reported that approximately 697 million people worldwide exhibit a reduced estimated glomerular filtration rate\(^5\). A normal gut flora is involved in the general well-being of humans. However, alterations of gut microbiology can increase the risk of several diseases. In this narrative review, we summarized the current understanding of the association between gut dysbiosis and CKD. We searched PubMed using keywords such as, “gut dysbiosis,” “chronic kidney disease,” “gut dysbiosis and chronic kidney disease,” and “probiotics” and selected relevant publications. We explored the mutual association between gut dysbiosis and CKD, analyzed the various mechanisms through which gut dysbiosis causes or worsens CKD, and explored potential strategies to correct gut microbiology in patients with CKD in an aim to summarize the current understanding of the association between gut dysbiosis and CKD.

Evidence of gut dysbiosis involvement in CKD

Simenhoff \textit{et al.}\(^6\) first described an altered gut microenvironment in patients with CKD. A 1984 study by Werder \textit{et al.}\(^7\) reported that renal disease was rarely observed in mice raised in a pathogen-free environment. Another study found that kd/kd mice with intestinal nephritis had a significantly reduced disease incidence after being transferred to a germ-free environment\(^8\). Studies recorded decreased numbers of culturable anaerobic bacteria and increased numbers of culturable aerobic bacteria in the feces of patients with CKD compared with the findings in healthy individuals\(^9\). Viziri \textit{et al.}\(^10\) observed that compared with the results in sham controls, rats with induced CKD had greater bacterial abundance and increased blood pressure and serum levels of creatinine and urea.

Mechanism by which gut dysbiosis influences CKD

The association between the intestine and kidneys is termed the gut–kidney axis\(^11\). The gut microbiota is involved in maintaining homeostasis through constant communication with vital organs. A healthy gut environment is crucial for regulating normal barrier function, and an abnormal gut microbiota is associated with increased risks of cancer and metabolic disorders\(^12\). Normal gut microbiota-derived short-chain fatty acids stimulate glucagon-like peptide-1 secretion, which exerts protective effects against renal oxidative stress and chronic hyperglycemia\(^13\). Gut dysbiosis is characterized by an abnormal intestinal microbiota composition, which causes metabolic dysfunction, immune disorders, and endocrine abnormalities, all of which can cause or worsen CKD\(^11\). Studies reported an enormously increased abundance of the phyla Proteobacteria and Fusobacteria and genera \textit{Escherichia}, \textit{Shigella}, \textit{Desulfovibrio}, and \textit{Streptococcus} in patients with CVD, whereas the abundance of the genera \textit{Roseburia}, \textit{Faecalibacterium}, \textit{Pyramidobacter}, \textit{Prevotellaceae} UCG-001, and \textit{Prevotella} was lower\(^14\). The association between CKD and gut dysbiosis has not been completely elucidated, and most
prior studies had various limitations. The immune disturbance in gut dysbiosis causes the abnormal proliferation and differentiation of lymphocytes, leading to the production of autoantibodies associated with CKD. Pathobionts activate helper T cells and increase the production of lipopolysaccharides, thereby triggering the pro-inflammatory immune response. Furthermore, intestinal microorganisms produce metabolic proteins and choline, including indoxyl sulfate (IS), trimethylamine-N-oxide (TMAO), phenylacetylglutamine (PAG), and \( p \)-cresyl sulfate (PCS). These metabolites play crucial roles in deteriorating renal and cardiovascular function. Intestinal microorganisms can also cause neuroendocrine dysfunction, which can aggravate CKD. Gut dysbiosis impairs the energy supply to the colonic epithelium and increases epithelial permeability, leading to a “leaky gut.”

Hypertension (HTN) is the most common risk factor of CKD. Gut dysbiosis activates the renin–angiotensin system, leading to HTN and diabetic nephropathy. Gut dysbiosis in patients with CKD is also involved in insulin resistance, and it causes dyslipidemia and triglyceridemia. Studies reported that the gut microbiota is also associated with other renal diseases, such as membranous nephropathy and diabetic kidney disease. Tao et al. proposed that gut microbiota-associated biomarkers can be used to differentiate membranous nephropathy and diabetic kidney disease in patients in whom renal biopsy is contraindicated. Abnormal numbers of gut microbes have been observed in patients with IgA nephropathy. Experimental studies revealed the presence of commensal flora-dependent IgA nephropathy in mice overexpressing B-cell activating factor, which is involved in IgA synthesis. Studies also detected gut dysbiosis in animal models of systemic lupus erythematosus (SLE). In addition, studies observed abnormal numbers of gut microbes in the feces of patients with SLE. Decreased diversity of the gut microbiota and the translocation of microbial components from the leaky gut to the liver are mainly responsible for the activation of lupus antibodies. Both lupus nephritis and IgA nephropathy participate in the development of CKD.

### Effects of CKD on gut dysbiosis

The association between gut dysbiosis and CKD is bidirectional. CKD itself can lead to alterations of the normal gut microbiota. The use of antibiotics and the specific diet consumed by patients with CKD can increase the risk of gut dysbiosis. A typical CKD diet, which is low in sodium, potassium, and phosphate, impairs the absorption of essential nutrients from food, including dietary fibers. Dietary fibers produce short-chain fatty acids, which protect against intestinal damage. Furthermore, renal function declines as CKD progresses, leading to the retention of uremic toxins. These urea-containing compounds accumulate in the intestine and blood, promoting the colonization of microorganisms that can use urea as an energy source. This changed gut microenvironment leads to gut dysbiosis and eventually to leaky gut syndrome.

### Gut dysbiosis and CKD complications

The relationship of gut dysbiosis with CKD is not limited to the primary disease, but it extends to complications such as HTN, cardiovascular diseases, cognitive abnormalities, and mineral and bone disorders. Cardiovascular complications are the major causes of mortality in patients with CKD. Gut dysbiosis promotes the development of cardiovascular events through the activation of immune complexes and the
production of pro-inflammatory cytokines and reactive oxygen species.\textsuperscript{32,33} Studies revealed that high levels of PCS\textsuperscript{34} and TMAO\textsuperscript{35} in patients with CKD are associated with an increased risk of cardiovascular complications and a high mortality rate. Cognitive decline is another common complication of CKD, which seriously impairs patient quality of life. Studies found that nearly 20\% of patients with CKD exhibit psychiatric diseases.\textsuperscript{36} Gut dysbiosis causes cognitive decline through effects on the hypothalamic–pituitary–adrenal axis and neurotransmitters.\textsuperscript{37} Additionally, gut dysbiosis-induced uremic toxin retention causes oxidative stress and endothelial dysfunction. Some uremic toxins, such as indoxyl sulfate, can cross the blood–brain barrier and accumulate in the brain, inducing inflammation and apoptosis in astrocytes and neuroglial tissues.\textsuperscript{38} Research illustrated that elevated levels of IS are associated with an increased incidence of cognitive dysfunction, and elevated IS levels represent a good indicator of mental health in patients with CKD.\textsuperscript{37,38} Further studies should be performed to elaborate the role of uremic toxins in the pathogenesis of psychiatric disorders in patients with CKD. Patients with CKD display poor bone quantity, which increases the risk of fractures, especially non-vertebral fractures.\textsuperscript{39,40} Studies indicated that the risk of fracture increases as CKD progresses.\textsuperscript{41} Vascular calcification is another complication of CKD that is characterized by calcium and phosphate crystal deposition in blood vessels and heart valves.\textsuperscript{42} Studies found that approximately 60\% of patients with advanced CKD have vascular calcification, which mostly arises in the tunica media layer.\textsuperscript{43} Vascular calcification is a major risk factor for cardiovascular disease. The presence of decreased bone quantity and vascular calcification, termed the calcification paradox, significantly increased the risk of morbidity and mortality in patients with CKD through fractures and cardiovascular disease.\textsuperscript{44} Gut dysbiosis also promotes the development of bone and mineral metabolism disorders in patients with CKD. As described previously, gut dysbiosis leads to the production of metabolic proteins, such as IS, TMAO, PAG, and PCS, and there is decreased renal clearance of these metabolites in patients with CKD. These metabolites, especially IS and PCS, aggravate vascular calcification through impaired autophagic flux in endothelial cells, miR-29b downregulation, and increased shedding of endothelial microparticles.\textsuperscript{43} Furthermore, multiple experimental and population-based studies reported associations of IS and PCS with thrombotic events, ischemic diseases, atrial fibrillation, and arterial stiffness.\textsuperscript{45–47} Furthermore, gut dysbiosis also elicits pro-inflammatory actions, which greatly increase the risk of decreased bone quantity and vascular calcification. The impaired gut epithelial barrier caused by the intestinal microbiota permits the entry of endotoxins into circulation, provoking an inflammatory reaction.\textsuperscript{48,49} The metabolites of protein fermentation are also associated with microinflammation. Inflammatory cytokines promote osteochondrogenic differentiation of vascular muscle cells and decrease fetuin-A production, which suppresses calcification.\textsuperscript{50} Once established, vascular calcification further promotes inflammatory responses in the body.

**Treatment strategies to correct gut dysbiosis**

The conservative management of CKD primarily involves dietary modification. Patients are encouraged to consume limited amounts of sodium, proteins, cholesterol, and potassium and increased amounts of fiber and vitamin-rich food. Diets lower in fiber, potassium, and phosphorus can cause bacterial overgrowth and increased uremic
toxin accumulation. A recent study by El Amouri et al. observed an inverse relationship between dietary fiber intake and the levels of protein-bound uremic toxins in the pediatric CKD population, highlighting the potential benefits of high dietary fiber intake in patients with CKD. Probiotics and prebiotics are being used in patients with CKD globally to correct gut dysbiosis. A laboratory study found that starch-containing prebiotics effectively improved gut dysbiosis and serum and urine metabolite levels in rats with CKD. Andrade-Oliveira et al. observed increased plasma short-chain fatty acid levels following probiotic treatment in mice with acute kidney injury. These fatty acids protected against renal ischemia. Additionally, probiotics have also been demonstrated to decrease pro-inflammatory cytokine levels in patients undergoing dialysis. Studies found reduced levels of uremic p-cresyl following probiotic treatment. Another study observed decreased IS levels following 5 weeks of probiotic treatment. A meta-analysis by Khalesi et al. demonstrated that probiotics effectively reduced both systolic and diastolic blood pressure. Multi-strain probiotics are more efficacious than single-strain preparations. A high daily dosage (≥1011 colony-forming units) for a long duration of more than 9 weeks is usually required. Scholars believe that the combination of probiotics and prebiotics may provide better efficacy. A study by Nakabayashi et al. revealed that symbiotics, which are combinations of probiotics and prebiotics, decreased serum p-cresol levels in nine patients undergoing hemodialysis. A recent study by Zhu et al. proposed that probiotics could delay the progression of CKD after administering Lactobacillus casei Zhang to correct bilateral renal ischemia/reperfusion-induced gut dysbiosis in mice. Their findings illustrated that probiotics exerted their effects through altering short-chain fatty acid and nicotinamide metabolism. Another recent study by Huang et al. indicated that multi-strain preparations of Lactobacillus improved renal function by reducing fibrosis-related proteins and improving intestinal barrier integrity, thereby further corroborating the notion that probiotics can delay the progression of CKD. Further studies with clinical endpoints, such as mortality and cardiovascular diseases, are required to explore the effects of probiotics in patients with CKD. Antibiotics are also occasionally used to treat an abnormal intestinal microecology. The use of antibiotics improves gut dysbiosis as well as HTN and renal function in patients with CKD. Minocycline has proven effective in reducing blood pressure and improving gut microbiota in rats with HTN. Qi et al. discovered that a combination of multiple antibiotics without any anti-hypertensive drugs reduced blood pressure by 70 mmHg in a patient with resistant HTN. Drug elimination through the kidneys can be impaired in patients with CKD; therefore, antibiotics should be used cautiously.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Ethics approval and consent to participate
Ethical approval was not required because of the nature of this study (narrative review).

Funding
The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This study was funded by the Construction of Discipline Innovation Team of Shaanxi University of Traditional Chinese Medicine (grant no. 2019-YL04) and Lei Genping Innovation Studio Construction Project of Shaanxi Education, Culture and Health system.
ORCID iD

Genping Lei https://orcid.org/0000-0002-8046-0511

References

1. Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. *Lancet* 2012; 379: 815–822.
2. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. *JAMA* 2007; 298: 2038–2047.
3. Chen TK, Knicely DH and Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. *JAMA* 2019; 322: 1294–1304.
4. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. *Lancet* 2013; 382: 260–272.
5. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; 392: 1789–1858.
6. Simenhoff ML, Saukkonen JJ, Burke JF, et al. Bacterial populations of the small intestine in uremia. *Nephron* 1978; 22: 63–68.
7. Werder AA, Amos MA, Nielsen AH, et al. Comparative effects of germfree and ambient environments on the development of cystic kidney disease in CFWwd mice. *J Lab Clin Med* 1984; 103: 399–407.
8. Hallman TM, Peng M, Meade R, et al. The mitochondrial and kidney disease phenotypes of kd/kd mice under germfree conditions. *J Autoimmun* 2006; 26: 1–6.
9. Ranganathan N, Friedman EA, Tam P, et al. Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada. *Curr Med Res Opin* 2009; 25: 1919–1930.
10. Vaziri ND, Wong J, Pahl M, et al. Chronic kidney disease alters intestinal microbial flora. *Kidney Int* 2013; 83: 308–315.
11. Meijers B, Evenepoel P and Anders HJ. Intestinal microbiome and fitness in kidney disease. *Nat Rev Nephrol* 2019; 15: 531–545.
12. Evenepoel P, Poesen R and Meijers B. The gut-kidney axis. *Pediatr Nephrol* 2017; 32: 2005–2014.
13. Everard A and Cani PD. Gut microbiota and GLP-1. *Rev Endocr Metab Disord* 2014; 15: 189–196.
14. Zhao J, Ning X, Liu B, et al. Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review. *Ren Fail* 2021; 43: 102–112.
15. Honda K and Littman DR. The microbiota in adaptive immune homeostasis and disease. *Nature* 2016; 535: 75–84.
16. Lu CC, Ma KL, Ruan XZ, et al. Intestinal dysbiosis activates renal renin-angiotensin system contributing to incipient diabetic nephropathy. *Int J Med Sci* 2018; 15: 816–822.
17. Koppe L, Pelletier CC, Alix PM, et al. Insulin resistance in chronic kidney disease: new lessons from experimental models. *Nephrol Dial Transplant* 2014; 29: 1666–1674.
18. Khan MT, Nieuwdorp M and Backhed F. Microbial modulation of insulin sensitivity. *Cell Metab* 2014; 20: 753–760.
19. Yang T, Richards EM, Pepine CJ, et al. The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease. *Nat Rev Nephrol* 2018; 14: 442–456.
20. Poesen R, Windey K, Neven E, et al. The Influence of CKD on Colonic Microbial Metabolism. *J Am Soc Nephrol* 2016; 27: 1389–1399.
21. Tao S, Li L, Li L, et al. Understanding the gut-kidney axis among biopsy-proven diabetic nephropathy, type 2 diabetes mellitus and healthy controls: an analysis of the gut microbiota composition. *Acta Diabetol* 2019; 56: 581–592.
22. De Angelis M, Montemurno E, Piccolo M, et al. Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). *PLoS One* 2014; 9: e99006.
23. Fagarasan S, Kawamoto S Kanagawa O, et al. Adaptive immune regulation in the gut: T cell-dependent and T cell-independent IgA synthesis. *Annu Rev Immunol* 2010; 28: 243–273.
24. Zhang H, Liao X, Sparks JB, et al. Dynamics of gut microbiota in autoimmune lupus. *Appl Environ Microbiol* 2014; 80: 7551–7560.

25. Zegarra-Ruiz DF, El Beidaq A, Iñiguez AJ, et al. A Diet-Sensitive Commensal Lactobacillus Strain Mediates TLR7-Dependent Systemic Autoimmunity. *Cell Host Microbe* 2019; 25: 113–127.e6.

26. Van Der Meulen TA, Harmsen HJM, Vila AV, et al. Shared gut, but distinct oral microbiota composition in primary Sjögren’s syndrome and systemic lupus erythematosus. *J Autoimmun* 2019; 97: 77–87.

27. Manfredo Vieira S, Hiltensperger M, Kumar V, et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. *Science* 2018; 359: 1156–1161.

28. Lau WL, Chang Y and Vaziri ND. The consequences of altered microbiota in immune-related chronic kidney disease. *Nephrol Dial Transplant* 2021; 36: 1791–1798. DOI: 10.1093/ndt/gfaa087.

29. Mahmoodpoor F, Rahbar Saadat Y, Barzegari A, et al. The impact of gut microbiota on kidney function and pathogenesis. *Biomed Pharmacother* 2017; 93: 412–419.

30. Plata C, Cruz C, Cervantes LG, et al. The gut microbiota and its relationship with chronic kidney disease. *Int Urol Nephrol* 2019; 51: 2209–2226.

31. Yang J, Lim SY, Ko YS, et al. Intestinal barrier disruption and dysregulated mucosal immunity contribute to kidney fibrosis in chronic kidney disease. *Nephrol Dial Transplant* 2019; 34: 419–428.

32. Park GH, Song JW, Lee CM, et al. Long-term prognosis of end-stage renal disease patients with normal myocardial perfusion as determined by single photon emission computed tomography. *Korean J Intern Med* 2018; 33: 148–156.

33. Baek SH, Cha RH, Kang SW, et al. Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease. *Korean J Intern Med* 2019; 34: 858–866.

34. Lin CJ, Wu V, Wu PC, et al. Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure. *PLoS One* 2015; 10: e0132589.

35. Heianza Y, Ma W, Manson JE, et al. Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta-Analysis of Prospective Studies. *J Am Heart Assoc* 2017; 6: e004947.

36. Kim SM and Song IH. The clinical impact of gut microbiota in chronic kidney disease. *Korean J Intern Med* 2020; 35: 1305–1316.

37. Lin YT, Wu PH, Liang SS, et al. Protein-bound uremic toxins are associated with cognitive function among patients undergoing maintenance hemodialysis. *Sci Rep* 2019; 9: 20388.

38. Watanabe I, Tatebe J, Namba S, et al. Activation of aryl hydrocarbon receptor mediates indoxyl sulfate-induced monocyte chemoattractant protein-1 expression in human umbilical vein endothelial cells. *Circ J* 2013; 77: 224–230.

39. Chen H, Lips P, Vervloet MG, et al. Association of renal function with bone mineral density and fracture risk in the Longitudinal Aging Study Amsterdam. *Osteoporos Int* 2018; 29: 2129–2138.

40. Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. *Kidney Int* 2017; 92: 26–36.

41. Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. *Kidney Int* 2006; 70: 1358–1366.

42. Vervloet M and Cozzolino M. Vascular calcification in chronic kidney disease: different bricks in the wall?. *Kidney Int* 2017; 91: 808–817.

43. Evenepoel P, Dejongh S, Verbeke K, et al. The Role of Gut Dysbiosis in the Bone-Vascular Axis in Chronic Kidney Disease. *Toxins (Basel)* 2020; 12: 285.

44. Evenepoel P, Opdebeeck B, David K, et al. Bone-Vascular Axis in Chronic Kidney Disease. *Adv Chronic Kidney Dis* 2019; 26: 472–483.
45. Meijers BKI, Claes K, Bammens B, et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 2010; 5: 1182–1189.

46. Liabeuf S, Barreto DV, Barreto FC, et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010; 25: 1183–1191.

47. Viaene L, Thijs L, Jin Y, et al. Heritability and clinical determinants of serum indoxyl sulfate and p-cresyl sulfate, candidate biomarkers of the human microbiome enterotype. PLoS One 2014; 9: e79682.

48. Meijers B, Farré R, Dejongh S, et al. Intestinal Barrier Function in Chronic Kidney Disease. Toxins (Basel) 2018; 10: 298. DOI: 10.3390/toxins10070298.

49. Lau WL, Kalantar-Zadeh K and Vaziri ND. The Gut as a Source of Inflammation in Chronic Kidney Disease. Nephron 2015; 130: 92–98.

50. Henze LA, Luong TTD, Boehme B, et al. Impact of C-reactive protein on osteo-/chondrogenic transdifferentiation and calcification of vascular smooth muscle cells. Aging (Albany NY) 2019; 11: 5445–5462.

51. Crespo-Salgado J, Vehaskari VM, Stewart T, et al. Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study. Microbiome 2016; 4: 50.

52. El Amouri A, Snaeuwaert E, Foulon A, et al. Dietary fibre intake is low in paediatric chronic kidney disease patients but its impact on levels of gut-derived uremic toxins remains uncertain. Pediatr Nephrol 2021; 36: 1589–1595.

53. Kieffer DA, Piccolo BD, Vaziri ND, et al. Resistant starch alters gut microbiome and metabolomic profiles concurrent with amelioration of chronic kidney disease in rats. Am J Physiol Renal Physiol 2016; 310: F857–F871.

54. Andrade-Oliveira V, Amano MT, Correa-Costa M, et al. Gut Bacteria Products Prevent AKI Induced by Ischemia-Reperfusion. J Am Soc Nephrol 2015; 26: 1877–1888.

55. Wang IK, Wu YY, Yang YF, et al. The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial. Benef Microbes 2015; 6: 423–430.

56. Rossi M, Johnson DW, Morrison M, et al. Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial. Clin J Am Soc Nephrol 2016; 11: 223–231.

57. Ramezani A, Massy ZA, Meijers B, et al. Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target. Am J Kidney Dis 2016; 67: 483–498.

58. Takayama F, Taki K and Niwa T. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am J Kidney Dis 2003; 41: S142–S145.

59. Khalesi S, Sun J, Buys N, et al. Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension 2014; 64: 897–903.

60. Nakabayashi I, Nakamura M, Kawakami K, et al. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrol Dial Transplant 2011; 26: 1094–1098.

61. Zhu H, Cao C, Wu Z, et al. The probiotic L. casei Zhang slows the progression of acute and chronic kidney disease. Cell Metab 2021; S1550-4131(21)00284-9. DOI: 10.1016/j.cmet.2021.06.014.

62. Huang H, Li K, Lee Y, et al. Preventive Effects of Lactobacillus Mixture against Chronic Kidney Disease Progression through Enhancement of Beneficial Bacteria and Downregulation of Gut-Derived Uremic Toxins. J Agric Food Chem 2021; 69: 7353–7366.

63. Yang T, Santisteban MM, Rodriguez V, et al. Gut dysbiosis is linked to hypertension. Hypertension 2015; 65: 1331–1340.

64. Qi Y, Aranda JM, Rodriguez V, et al. Impact of antibiotics on arterial blood pressure in a patient with resistant hypertension - A case report. Int J Cardiol 2015; 201: 157–158.